Word on the street is a big pharma company is looking to get into cell and genetic therapy and Vertex has the playbook for it. The overweight stock took a hit this week and Wall Street agrees it is priced too high.
The leadership at the company is not stellar and the luck they have had is due to Liden and having a monopoly on CF. Liden is less involved and growth for Vertex in the CF market will start to slow as their market access has been gained in most areas at this point.
Big pharma take over makes 100% sense at this point and cleaning house at the top would be a benefit to the success of the pipeline.
An acquisition would keep some of the R&D staff, but the other functions would go and the company has no sales force for CF, so home office employees would be put on the street. The company is also too heavy in R&D with it enough results based in the investments. Nothing would be officially announce until 1st quarter or early 2nd quarter.
The leadership at the company is not stellar and the luck they have had is due to Liden and having a monopoly on CF. Liden is less involved and growth for Vertex in the CF market will start to slow as their market access has been gained in most areas at this point.
Big pharma take over makes 100% sense at this point and cleaning house at the top would be a benefit to the success of the pipeline.
An acquisition would keep some of the R&D staff, but the other functions would go and the company has no sales force for CF, so home office employees would be put on the street. The company is also too heavy in R&D with it enough results based in the investments. Nothing would be officially announce until 1st quarter or early 2nd quarter.